Immune response in addicts with chronic hepatitis C treated with interferon and ribavirine

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 1, 2007, Pages 74-79

  Sergio, Neri ^a,c   Salvatore, Travali ^a   Bertino, Gaetano ^a   Davide, Pulvirenti ^a   Claudio, Italiano ^b   Massimo, Libbra ^a   Barbara, Mauceri ^a   Giuseppe, Abate ^a   Stefano, Calvagno ^a   Danila, Cilio ^a   Aikaterini, Tsami ^a   Luca, Ignaccolo ^a   Daniela, Callari ^a   Luciano, Caruso ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Detoxification Department   (Italy)

^c Detoxification Department Territorial Health Unit ^*  (Italy)

Author keywords

Addiction; Chronic hepatitis C; Immune system; Interferon; Ribavirine

Indexed keywords

DIAMORPHINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; METHADONE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DEPRESSION; DETOXIFICATION; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKOCYTE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METHADONE TREATMENT; NATURAL KILLER CELL; PATIENT COMPLIANCE; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; THYROID DISEASE;

EID: 33845637261     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04423.x     Document Type: Article

References (48)

1. EASL International Consensus Conference on Hepatitis C. Consensus statement. J. Hepatol. 1999; 30: 956-61.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1996; 26 (Suppl. 1): 62s.
3. Hoofnagle JH, Hepatitis C. The clinical spectrum of disease. Hepatology 1997; 26 (Suppl. 1): 15s.
4. Centers of Disease Control and Prevention Recommendations for prevention and control of HCV infection and HCV-related chronic diseases. MMVR 1998; 47 (RR19): 1.
5. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug abusers. Hepatology 2001; 34: 187-93.
6. Panasink A, Prokopowicz D, Zac J. Immunological response in chronic hepatitis C virus infection during interferon alpha therapy. Hepatogastroenterology 2004; 51: 1088-92.
7. Akdis C, Blaser K. Mechanism of interleukin-10-mediated immune suppression. Immunology 2001; 103: 131-6.
8. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirine treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
9. Amara R, Mareckova H, Urbanek P, Fucikova T. Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C. J. Gastroenterol. 2003; 38: 254-9.
10. Diaz T, Des Jarlois DC, Vlahov D, Perlis T, Edwards V. Factors associated with prevalent hepatitis C: difference among young adult injection drug users in lower and upper Manhattan New York City. Am. J. Public Health 2001; 91: 23-6.
11. Roy S, Loh HH. Effects of opioids on the immune system. Neurochem. Res. 1996; 21: 1375-86.
12. Neri S, Bruno CM, Abate G et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin. Ther. 2002; 24: 1627-35.
13. Willmann K, Dunne JF. A flow cytometric immune function assay for human peripheral blood dentritic cells. J. Leukocyte Biol. 2000; 67: 536-44.
14. Mazzarino C, Nicosia A, Monte D et al. IL-2 receptors, NK and LAK cytotoxicity of lymphocytes in breast carcinoma during prolonged thymopentin therapy. J. Nucl. Med. Allied S. 1990; 34: 161-2.
15. Scheuer PJ. Classification of chronic viral hepatitis: a need for assessment. J. Hepatol. 1991; 13: 372-4.
16. Marinho RT, Pinto R, Santos ML, Lobos IV, Moura MC. Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. J. Viral Hepat. 2004; 11: 206-16.
17. Biron CA, Nguyen KB, Pien GC, Cousens CP, Salazar-Mather TP. Natural killer cells in antiviral defence: function and regulation by innatecytokine. Ann. Rev. Immunol. 1999; 17: 189-200.
18. Rahman F, Heller T, Sobao Y et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004; 40: 87-97.
19. Roda LG, Bongiorno L, Trani E, Urbani A, Marini M. Review paper. Positive and negative immunomodulation by opioid peptides. Int. J. Immunopharmaco. 1996; 18: 1-16.
20. Donahoe RM, Madden JJ, Hollingsworth F, Shafer D, Falek A. Morphine depression of T cell E-rosetting: definition of the process. Fed. Proc. 1985; 44: 95-9.
21. Novick DM, Ochshorn M, Ghali V et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther. 1989; 250: 606-10.
22. Carr DJ, Rogers TJ, Weber RJ. The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis. Proc. Soc. Exp. Biol. Med. 1996; 213: 248-57.
23. Blalock JE. The syntax of immune-neuroendocrine communication. Immunol. Today 1994; 15: 504-11.
24. Hernandez MC, Flores LR, Bayer BM. Immunosuppression by morphine is mediated by central pathways. J. Pharmacol. Exp. Ther. 1993; 267: 1336-41.
25. Shavit Y, Depaulis A, Martin FC et al. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc. Natl. Acad. Sci. USA 1986, 7114-17.
26. Makman MH, Bilfinger TV, Stefano GB. Human granulocytes contain an opiate alkaloid-selective receptor mediating inhibition of cytokine-induced activation and chemotaxis. J. Immunol. 1995; 154: 1323-30.
27. Chao CC, Molitor TW, Close K, Hu S, Peterson PK. Morphine inhibits the release of tumor necrosis factor in human peripheral blood mononuclear cell cultures. Int. J. Immunopharmaco. 1993; 15: 447-53.
28. Peterson PK, Molitor TW, Chao CC. Mechanisms of morphine-induced immunomodulation. Biochem. Pharmacol. 1993; 46: 343-8.
29. Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J. Pharmacol. Exp. Ther. 1993; 267: 703-6.
30. Peng X, Masser DM, Adler MW, Rogers TJ, Miessler JJ, Eisenstein TK. Morphine enhances interleukin-12 and the production of other pro-inflammatory cytokines in mouse peritoneal macrophages. J. Leukocyte Biol. 2000; 68: 723-8.
31. Tubaro E, Borelli G, Croce C, Cavallo G, Santiangeli C. Effect of morphine on resistance to infection. J. Infect. Dis. 1983; 148: 656-66.
32. West JP, Lysle DT, Dykstra LA. Tolerance development to morphine-induced alterations of immune status. Drug Alcohol Depend. 1997; 46: 147-57.
33. Pacifici R, Di Carlo S, Bacosi A, Pichini S, Zuccaro P. Pharmokinetics and cytokine production in heroin and morphine-treated mice. Int. J. Immunopharmaco. 2000; 22: 203-614.
34. Bayer BM, Daussin S, Hernandez M, Irvin L. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology 1990; 29: 369-74.
35. Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF. Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J. Clin. Invest. 1987; 80: 824-31.
36. Pacifici R, Patrini G, Venier I, Parolaro D, Zuccaro P, Gori E. Effect of morphine and methadone acute treatment on immunological activity in mice: pharmacokinetic and pharmacodynamic correlates. J. Pharmacol. Exp. Ther. 1994; 269: 1112-16.
37. Mellon RD, Bayer BM. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism (s) of action. J. Neuroimmunol. 1998; 83: 19-28.
38. Ruff MR, Wahl SM, Mergenhagen S, Pert CB. Opiate receptor-mediated chemotaxis of human monocytes. Neuropeptides 1985; 5: 363-6.
39. Bryant HU, Bernton EW, Holaday JW. Morphine pellet-induced immunomodulation in mice: temporal relationships. J. Pharmacol. Exp. Ther. 1988; 245: 913-20.
40. Yeager MP, Colacchio TA, Yu CT et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995; 83: 500-8.
41. Ayesta FJ, Florez J. Tolerance to respiratory actions of sufentanil: functional tolerance and route-dependent differential tolerance. J. Pharmacol. Exp. Ther. 1989; 250: 371-8.
42. Bussiere JL, Adler MW, Rogers TJ, Eisenstein TK. Cytokine reversal of morphine-induced suppression of the antibody response. J. Pharmacol. Exp. Ther. 1993; 264: 591-7.
43. Nair MP, Laing TJ, Schwartz SA. Decreased natural and antibody-dependent cellular cytotoxic activities in intravenous drug abusers. Clin. Immunol. Immunop. 1986; 38: 68-78.
44. Kreek MJ. Long-term pharmacotherapy for opiate (primarily heroin) addiction: opioid agonists. In: Schuster CR, Kuhar MJ, eds. Pharmacological Aspects of Drug Dependency. Toward an Integrated Neurobehavioral Approach. New York: Springer, 1996; 487-562.
45. De Aranjo MS, Guerret S, Gerard F, Chossegros P, Chevallier M, Grimaud JA. Quantitative studies on liver fibrosis and alpha-smooth muscle actin expression in heroin abusers. Int. J. Immunopharmaco. 2000; 22: 603-14.
46. Robayes G, Buntinx F. Treatment of hepatitis C viral infection in substance abusers. Acta Gastroenterol. Belg. 2005; 68: 55-67.
47. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis in patients with drug dependence. Time to change the rules? Addiction 2004; 99: 1167-75.
48. Sylvestre DL. Treating hepatitis C in methadone patients: an intérim analysis. Drug Alcohol Depend. 2002; 67: 117-23.